Antibiotic Development Needs Economic Incentives

  02 March 2021

The antibiotic market is categorically different from that of other pharmaceuticals. Research and development of any drug is expensive, but antibiotics have comparatively low prices and sales volume.

As a result, the companies making them are going bankrupt, and many potentially lifesaving drugs end up falling into an antibiotic valley of death—dropping out of production before they can reach patients.


Further reading: PEW
Author(s): Wes Kim
Smart Innovations  


Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified

Technology Database

Display your AMR Technology, Product and Service


Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.


Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!